Retatrutide
One of the most closely watched compounds in metabolic research right now — with genuinely major published Phase 3 results, and, as of this writing, still no regulatory approval anywhere. This is a fast-moving area; check the review date below.
Retatrutide (LY3437943) — also sold in research form as GLP-3RT
Synthetic triple-receptor agonist peptide
Metabolic — obesity, weight management, related comorbidities
Yes — large Phase 2 and Phase 3 published trials
Investigational — no FDA, MHRA, or EMA approval identified as of this review
5 October 2026
Retatrutide is a synthetic peptide developed by Eli Lilly that activates three separate hormone receptors at once: GIP, GLP-1, and glucagon. That "triple agonist" design is what distinguishes it from earlier compounds in the same broad family (which typically act on one or two of these receptors), and it's the basis for most of the scientific interest in it.
GIP, GLP-1, and glucagon receptors each play separate roles in appetite, blood sugar regulation, and energy expenditure. The hypothesis behind combining all three in one molecule is that their effects might be complementary rather than redundant — and the published trial results (below) have been large enough to draw serious attention from the metabolic research field and the pharmaceutical industry alike.
Established
Retatrutide binds and activates GIP, GLP-1, and glucagon receptors — this receptor pharmacology is well-characterised and is how the compound is classified and described throughout the literature.
Still being worked out
Precisely how the three receptor activities combine to produce the magnitude of effect seen in trials — and which effects come from which receptor — is still an active research question, not a fully settled mechanism.
Laboratory / In-vitro
Receptor-binding pharmacology across all three target receptors.
Animal / Preclinical
Preclinical pharmacology supporting the triple-agonist mechanism ahead of human trials.
Early & Controlled Human Research
Phase 2 (338 participants, published NEJM 2023) and Phase 3 TRIUMPH-1 (2,335 participants, published NEJM 2026), plus multiple other TRIUMPH-programme trials at various stages.
Established Clinical Evidence / Approval
Not yet — see Regulatory context below.
- Population/model
- 338 adults with obesity or overweight
- Design
- Randomized, double-blind, placebo-controlled, Phase 2
- What researchers found
- Up to 17.5% mean weight reduction at 24 weeks; up to 24.2% at 48 weeks (secondary endpoint)
- Major limitation
- Phase 2 scale (hundreds, not thousands); shorter follow-up than the later Phase 3 programme
- Population/model
- 2,335 adults with obesity or overweight, including sub-cohorts with knee osteoarthritis and obstructive sleep apnea
- Design
- Randomized, double-blind, placebo-controlled, Phase 3, 80-week treatment period
- What researchers found
- Average weight loss of 28.3% at 80 weeks on the 12mg dose
- Major limitation
- Very recent publication — independent replication and longer-term follow-up are still pending
Retatrutide has one of the most extensive registered trial programmes of any compound discussed on this site — the TRIUMPH programme alone includes multiple Phase 3 studies across different populations and endpoints (obesity, cardiovascular/kidney outcomes, type 2 diabetes, and others), at different stages of completion.
NCT04881760
Phase 2 obesity trial. Completed, results published (above).
NCT05929066 (TRIUMPH-1)
Phase 3 obesity trial. Completed; published in NEJM, though the registry's own structured results module had not yet posted results as of this review — a timing gap between registry and journal, not a discrepancy in the finding itself.
NCT06383390 (TRIUMPH-Outcomes)
Phase 3 cardiovascular/kidney outcomes trial. Active, not recruiting; estimated 10,000 participants; no results yet.
Other TRIUMPH trials
Additional registered studies exist across different populations (e.g. type 2 diabetes, chronic kidney disease) at varying stages — see the Tracker and ClinicalTrials.gov directly for the current full picture.
See retatrutide trials in the Clinical Trials Tracker → · Full detail on TRIUMPH-1 →
"Retatrutide is the next big approved weight-loss drug — it's basically already on the market."
Large, published, peer-reviewed Phase 2 and Phase 3 trials showing substantial average weight reduction — genuinely strong human evidence by the standards of this site.
That retatrutide has shown a large effect in well-conducted trials for weight reduction in adults with obesity/overweight. It does not support the claim that it's approved or available as a prescribed medicine anywhere — as of this review, it is not.
Final long-term safety data, the outcome of the cardiovascular/kidney trial still underway, and the timing and outcome of any future regulatory decision.
Very recent publicationTRIUMPH-1 was published within weeks of this review — independent scrutiny and replication take time.
Long-term safety still pendingThe dedicated cardiovascular/kidney outcomes trial (TRIUMPH-Outcomes) is still active, not completed.
Not yet regulator-reviewedNo FDA, MHRA, or EMA assessment has concluded — the trials being positive is not the same as a regulator agreeing.
As of this review, retatrutide has not been approved by the FDA, MHRA, or EMA for any indication. Industry reporting suggests Eli Lilly may be approaching a regulatory submission, but we could not independently confirm an exact submission date or timeline from an official source. [VERIFICATION REQUIRED — exact submission/approval timeline] Treat any specific date you see elsewhere with caution and check the FDA/MHRA's own records directly. Read the full UK regulatory framework →
What We Still Don't Know
- Whether and when retatrutide will receive regulatory approval anywhere, and for what specific indication.
- Long-term cardiovascular and kidney safety — the dedicated trial for this is still running.
- How its effects and safety profile compare directly to other compounds in the same broader drug class, outside of indirect cross-trial comparison.
Jastreboff AM, et al., "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial," NEJM, 2023 (DOI 10.1056/NEJMoa2301972). Jastreboff AM, et al., TRIUMPH-1 results, NEJM, 29 September 2026 (DOI 10.1056/NEJMoa2604169). ClinicalTrials.gov records NCT04881760, NCT05929066, and NCT06383390, verified directly via the official registry API.